Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia

Published:2016-10-14 Issue:6 Volume:58 Page:1412-1423
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Seymour John F.¹,Döhner Hartmut²,Minden Mark D.³,Stone Richard⁴,Gambini Dominique⁵,Dougherty Donna⁵,Beach C.L.⁵,Weaver Jerry⁵,Dombret Hervé⁶

Affiliation:

1. Peter MacCallum Cancer Center, University of Melbourne, Parkville, Melbourne, Australia;

2. Universitätsklinikum Ulm, Ulm, Germany;

3. Princess Margaret Hospital, Toronto, Ontario, Canada;

4. Dana-Farber Cancer Institute, Boston, MA, USA;

5. Celgene Corporation, Summit, NJ, USA;

6. Hôpital Saint Louis, Institut Universitaire d’Hématologie, Paris, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1243680

Reference33 articles.

1. Acute Myeloid Leukemia

2. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

3. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

4. General Approach to, and Perspectives on Clinical Research in, Older Patients With Newly Diagnosed Acute Myeloid Leukemia

5. Acute myeloid leukemia: 2014 Update on risk-stratification and management

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD;Therapeutic Advances in Hematology;2022-01

2. Hypomethylating agents for elderly patients with acute myeloid leukemia: a PRISMA systematic review and meta-analysis;EUR REV MED PHARMACO;2021

3. Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the ‘real-world’;Leukemia & Lymphoma;2020-02-08

4. Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response;Clinical Lymphoma Myeloma and Leukemia;2020-02

5. Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives;Archives of Toxicology;2017-10-10